BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26301881)

  • 21. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
    Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
    Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients.
    Chen X; Wan J; Liu J; Xie W; Diao X; Xu J; Zhu B; Chen Z
    Lung Cancer; 2010 Sep; 69(3):348-54. PubMed ID: 20022135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.
    Koukourakis MI; Giatromanolaki A; Thorpe PE; Brekken RA; Sivridis E; Kakolyris S; Georgoulias V; Gatter KC; Harris AL
    Cancer Res; 2000 Jun; 60(11):3088-95. PubMed ID: 10850461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
    Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients.
    Seker MM; Sancaktar E; Acibucu DO; Filiz AK; Deveci K; Bahceci A; Kacan T; Babacan N; Yuce S
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2929-32. PubMed ID: 24254563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
    Dudek AZ; Mahaseth H
    Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
    Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
    J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer.
    Liu H; Gu X; Lv T; Wu Y; Xiao Y; Yuan D; Li Y; Song Y
    J Cancer Res Ther; 2014; 10(2):239-43. PubMed ID: 25022372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
    Shimanuki Y; Takahashi K; Cui R; Hori S; Takahashi F; Miyamoto H; Fukurchi Y
    Lung; 2005; 183(1):29-42. PubMed ID: 15793665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
    Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
    Zhao M; Gao FH; Wang JY; Liu F; Yuan HH; Zhang WY; Jiang B
    Lung Cancer; 2011 Sep; 73(3):366-74. PubMed ID: 21333372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
    Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
    Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients.
    Charpidou A; Gkiozos I; Konstantinou M; Eleftheraki A; Demertzis P; Harrington K; Polyzos A; Syrigos KN
    Cancer Lett; 2011 May; 304(2):144-53. PubMed ID: 21396771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers.
    Coelho AL; Araújo AM; Gomes MP; Catarino RJ; Andrade EB; Lopes AM; Medeiros RM
    Future Oncol; 2015; 11(24):3233-42. PubMed ID: 26562248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
    Azuma K; Kawahara A; Hattori S; Taira T; Tsurutani J; Watari K; Shibata T; Murakami Y; Takamori S; Ono M; Izumi H; Kage M; Yanagawa T; Nakagawa K; Hoshino T; Kuwano M
    J Thorac Oncol; 2012 May; 7(5):779-89. PubMed ID: 22481237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
    Volm M; Koomägi R; Mattern J
    Anticancer Res; 1996; 16(1):213-7. PubMed ID: 8615611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer.
    Koh E; Iizasa T; Yamaji H; Sekine Y; Hiroshima K; Yoshino I; Fujisawa T
    Int J Surg Pathol; 2012 Jun; 20(3):233-9. PubMed ID: 22334615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer].
    Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
    Pol Merkur Lekarski; 2007 Jun; 22(132):536-8. PubMed ID: 17874624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.